Phio Pharmaceuticals Corp. will participate in the Sidoti Micro-Cap Virtual Investor Conference on May 21-22, 2025. CEO and Chairman Robert Bitterman will present an update on the company's INTASYL siRNA technology and progress on the clinical trial with their lead compound PH-762 for treating skin cancers. The presentation is scheduled for 10:00 AM ET on May 22, and one-on-one investor meetings will be held on both days.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Phio Pharmaceuticals Corp. published the original content used to generate this news brief via Newsfile (Ref. ID: 252526) on May 19, 2025, and is solely responsible for the information contained therein.